Improvac (GnRH vaccine) offers a proven, welfare-positive alternative to surgical castration of male piglets for boar taint prevention. Despite its availability in 60+ countries and endorsement by major veterinary bodies, adoption remains limited in Europe due to market resistance and familiarity barriers.
Surgical castration without anaesthesia causes acute pain equivalent to a significant surgical wound. Piglets show elevated cortisol, vocalisation, and behavioural disruption for hours after the procedure. Immunocastration eliminates this welfare harm entirely: two injections under brief handling stress versus permanent surgical mutilation. The brief injection handling causes momentary stress but no lasting pain. Market resistance — primarily from retailers and consumers concerned about vaccine association with food products — is the primary barrier to adoption rather than any welfare or safety concern. Where immunocastration has been adopted at scale (Australia, Brazil, New Zealand), welfare outcomes are demonstrably superior to both surgical castration and entire male production in conventional systems.